Role ofdoxorucin in pathogenesis of remodulution of left ventricle of the hart and cardiac insufficient in breast cancer patients

The present study was undertaken to evaluate the mechanisms of re-modulation of left ventricle (LV), its determinant and hemodynamic effects depending on doxorubicin dose in breast cancer patients. A total of 42 patients who received chemotherapy with doxorubicin for breast cancer were examined. Echocardiography study of linear and volume parameters of LV, systolic function and re-modulation was carried out at various doxorubicin doses. The patients were divided into 3 groups with respect to doxorubicin doses, which were as follows: 108,66 ± 4,66 mg/m2, 193,45 ± 4,37 mg/m2 and 304,02 ± 4,75 mg/m2. Cardiotoxic effect of doxorubicin began to be manifested at a dose of 108,66 ± 4,66 mg/m2 by launching the mechanisms of LV remodulation and dose-dependent changes in LV myocardium. Re-modulation of LV was characterized by the development of eccentric hypertrophy in the first two groups and in concentric hypertrophy in the third group of patients.